AstraZeneca: Prostatic Neoplasms trials

The registry lists 91 Prostatic Neoplasms studies with AstraZeneca as lead sponsor. 15 are open to participants now and 15 have results posted.

Phase 1 24Phase 2 27Phase 3 17Phase 4 4No phase 30(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)RecruitingNCT07711002Phase 3
• PROLONG (PRostateOLaparibONcombinationGcc) StudyNot yet recruitingNCT07674121
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)RecruitingNCT07611110Phase 3
• Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerRecruitingNCT07590934Phase 1/2
• PROMET-BR - Molecular Profiling of Metastatic Prostate Cancer: a Brazilian CohortNot yet recruitingNCT07560215
• First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate CancerRecruitingNCT07529717Phase 1/2
• A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate CancerRecruitingNCT07192614Phase 1/2
• Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate CancerRecruitingNCT07181161Phase 1/2
• DESTINY-PANTUMOUR04RecruitingNCT07124000
• Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDerationRecruitingNCT07052578
• A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationRecruitingNCT06952803Phase 3
• A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerRecruitingNCT06879041Phase 1
• Study of AZD0754 in Participants With Metastatic Prostate CancerRecruitingNCT06267729Phase 1/2
• LTFU for All Cell and Gene Therapy StudiesNot yet recruitingNCT06194461
• Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT05417594Phase 1/2
• Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsActive, not recruitingNCT05457257Phase 4Results posted
• Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)Active, not recruitingNCT05171816Phase 3Results posted
• A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.CompletedNCT04495179Phase 2Results posted
• Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyActive, not recruitingNCT04493853Phase 3Results posted
• An Open-label, Phase II Study of AZD4635 in Patients With Prostate CancerCompletedNCT04089553Phase 2Results posted
• Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT03732820Phase 3Results posted
• Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)CompletedNCT02987543Phase 3Results posted
• Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.CompletedNCT01972217Phase 2Results posted
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate CancerTerminatedNCT00626548Phase 3Results posted
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate CancerCompletedNCT00617669Phase 3Results posted
• Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone DiseaseCompletedNCT00558272Phase 2Results posted
• A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone MetastasesCompletedNCT00554229Phase 3Results posted
• A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.CompletedNCT00378482Phase 2Results posted
• ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA)CompletedNCT00090363Phase 2Results posted
• A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate CancerCompletedNCT00055471Phase 2Results posted
• A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer DrugsActive, not recruitingNCT07336446Phase 1/2
• Treatment Approaches and Biomarkers PRevalence In de Novo MEtastatic Hormone-sensitive Prostate Cancer in Russian FederationSuspendedNCT07146113
• FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT06909825Phase 2
• Real-life Experience in Brazil in Patients With Castration-resistant Prostate Cancer Treated With Olaparib+AbirateroneWithdrawnNCT06457854
• FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT06402331Phase 2
• Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)Active, not recruitingNCT06380738
• Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsActive, not recruitingNCT06120491Phase 3
• PRostate Olaparib Real World Evidence StudyActive, not recruitingNCT06031805
• A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.CompletedNCT05938270Phase 1
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate CancerActive, not recruitingNCT05367440Phase 1/2
• Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingNCT05348577Phase 3
• Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).Active, not recruitingNCT05219500Phase 2
• HRR Prevalence in LatAm PROSPECT StudyCompletedNCT04962880
• Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates CancerCompletedNCT04801186
• A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the BodyCompletedNCT04712396Phase 1
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
• Drug Intensive Monitoring Study of Olaparib in Clinical Practice Among Chinese PatientsCompletedNCT04560452
• 'OLAP' (OLAparib Regulatory Post-marketing Surveillance)CompletedNCT04553926
• Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World SettingCompletedNCT04425200
• A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerCompletedNCT04087174Phase 1
• A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.TerminatedNCT03971110Phase 4
• A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsCompletedNCT03811652Phase 1
• AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasCompletedNCT03205176Phase 1
• A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate CancerCompletedNCT03193060
• A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate CancerCompletedNCT02991911Phase 1
• A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid MalignanciesCompletedNCT02740985Phase 1
• Non-Interventional Study PREVENTCompletedNCT02155998
• Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor TumorsCompletedNCT02144051Phase 1
• Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.CompletedNCT01692262Phase 1
• An Open Label Prostate Cancer Study in Japanese PatientsCompletedNCT01351688Phase 1
• Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen AgentCompletedNCT01303692
• Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)CompletedNCT01284608
• Open Label Prostate Cancer StudyCompletedNCT01162395Phase 1
• Immediate Postoperative Adjuvant Hormonal Treatment in High Risk Localised or Locally Advanced Prostate Cancer Patients.CompletedNCT01123434
• Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen AgentCompletedNCT01025479
• PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated PatientsCompletedNCT01020604
• Protocol for the Specified Clinical Experience Investigation on the Single Use of Casodex® Tablet 80 mgCompletedNCT00919477
• Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With BicalutamideCompletedNCT00871585
• Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate CancerCompletedNCT00846976Phase 3
• Depiction of Prostate Cancer Treatment Alternatives in GreeceCompletedNCT00733213
• Quality of Life Analysis of Treatment in Patients With Prostate Cancer on Adjuvant Zoladex TherapyCompletedNCT00692874
• Study of Coronary Heart Disease (CHD) & Heart Failure (HF) Risk in Prostate Cancer Patients, Taking Casodex or NotCompletedNCT00688532
• (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate CancerCompletedNCT00673205Phase 3
• Casodex vs Placebo in Non-Metastatic Early Prostate CancerCompletedNCT00672282Phase 3
• Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate CancerCompletedNCT00668083
• Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate CancerCompletedNCT00657904Phase 3
• Casodex - Nolvadex CombinationCompletedNCT00637871Phase 2
• Casodex 150-mg Compassionate Use Trial for Subjects With Prostate CancerNo longer availableNCT00636259
• Open Label Trial to Assess Iressa in Prostate Cancer PatientsCompletedNCT00635856Phase 2
• Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEXCompletedNCT00590213Phase 4
• Evaluation of QoL, Tolerability and Use of Zoladex 10,8 SafeSystem for Advanced PCa - German IPEP TrialCompletedNCT00540059
• Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA & BAI in prOstate Cancer patieNtsCompletedNCT00523484
• Combination Casodex® and Iressa™ in Locally Advanced Prostate CancerCompletedNCT00319787Phase 2
• Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPCCompletedNCT00314782Phase 1
• Trial of Iressa in Prostate Cancer PatientsCompletedNCT00265070Phase 2
• CMAB vs IMAB in Metastatic Prostate CancerWithdrawnNCT00255268Phase 4
• Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or RadiotherapyCompletedNCT00241475Phase 2
• Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate CancerCompletedNCT00239291Phase 1/2
• Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate CancerCompletedNCT00233610Phase 3
• CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate CancerCompletedNCT00075192Phase 1/2
• MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate CancerCompletedNCT00072930Phase 2